At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 80 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro Following Single Dose Administration in Elderly and Younger Adults With Type 1 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Diabetes Mellitus, Type 1. Completed, enrolled 80 participants across 2 sites.
Detailed Summary
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in elderly and younger adults with type 1 diabetes mellitus. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be between 3 to 8 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2017
Primary CompletionNov 2017
TodayJul 2026
First PostedMay 24, 2017
Enrollment StartMay 24, 2017
Primary CompletionNov 18, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.1 years ago
Interventions
LY900014drug
Administered SC
Insulin Lisprodrug
Administered SC